Literature DB >> 23066913

Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.

J Lyth1, J Hansson, C Ingvar, E Månsson-Brahme, P Naredi, U Stierner, G Wagenius, C Lindholm.   

Abstract

BACKGROUND: Survival and prognostic factors for thin melanomas have been studied relatively little in population-based settings. This patient group accounts for the majority of melanomas diagnosed in western countries today, and better prognostic information is needed.
OBJECTIVES: The aim of this study was to use established prognostic factors such as ulceration, tumour thickness and Clark's level of invasion for risk stratification of T1 cutaneous melanoma.
METHODS: From 1990 to 2008, the Swedish Melanoma Register included 97% of all melanomas diagnosed in Sweden. Altogether, 13,026 patients with T1 melanomas in clinical stage I were used for estimating melanoma-specific 10- and 15-year mortality rates. The Cox regression model was used for further survival analysis on 11,165 patients with complete data.
RESULTS: Ulceration, tumour thickness and Clark's level of invasion all showed significant, independent, long-term prognostic information. By combining these factors the patients could be subdivided into three risk groups: a low-risk group (67·9% of T1 cases) with a 10-year melanoma-specific mortality rate of 1·5% (1·2-1·9%); an intermediate-risk group (28·6% of T1 cases) with a 10-year mortality rate of 6·1% (5·0-7·3%); and a high-risk group (3·5% of T1 cases) with a 10-year mortality rate of 15·6% (11·2-21·4%). The high- and intermediate-risk groups accounted for 66% of melanoma deaths within T1.
CONCLUSIONS: Using a population-based melanoma register, and combining ulceration, tumour thickness and Clark's level of invasion, three distinct prognostic subgroups were identified.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23066913     DOI: 10.1111/bjd.12095

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Authors:  Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry
Journal:  J Invest Dermatol       Date:  2016-06-25       Impact factor: 8.551

2.  Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.

Authors:  Eric J Stanelle; Klaus J Busam; Barrie S Rich; Emily R Christison-Lagay; Ira J Dunkel; Ashfaq A Marghoob; Allan Halpern; Daniel G Coit; Michael P La Quaglia
Journal:  J Pediatr Surg       Date:  2015-03-14       Impact factor: 2.545

3.  Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.

Authors:  Alexander M M Eggermont; Domenico Bellomo; Suzette M Arias-Mejias; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Dennis H Murphree; Mark R Pittelkow; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Barbara Rentroia-Pacheco; Renske Wever; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves
Journal:  Eur J Cancer       Date:  2020-10-05       Impact factor: 9.162

4.  Prognostic survival model for people diagnosed with invasive cutaneous melanoma.

Authors:  Peter D Baade; Patrick Royston; Philipa H Youl; Martin A Weinstock; Alan Geller; Joanne F Aitken
Journal:  BMC Cancer       Date:  2015-01-31       Impact factor: 4.430

Review 5.  Controversies in the diagnosis and treatment of early cutaneous melanoma.

Authors:  O A Orzan; A Șandru; C R Jecan
Journal:  J Med Life       Date:  2015 Apr-Jun

Review 6.  The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients.

Authors:  Mihaela Antohe; Anastasia Coman; Gabriela Turcu; Roxana Ioana Nedelcu; Alice Brinzea; Mihaela Balaban; Andreea Moroianu; Lorena Manea; Ionela Hulea; Elena Balasescu; Sabina Andrada Zurac; Mirela Cioplea; Cristiana Popp; Luciana Nichita; Daniela Adriana Ion
Journal:  Med Pharm Rep       Date:  2022-07-26

7.  The human melanoma proteome atlas-Defining the molecular pathology.

Authors:  Lazaro Hiram Betancourt; Jeovanis Gil; Yonghyo Kim; Viktória Doma; Uğur Çakır; Aniel Sanchez; Jimmy Rodriguez Murillo; Magdalena Kuras; Indira Pla Parada; Yutaka Sugihara; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Erika Velasquez; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Krzysztof Pawłowski; Jonatan Eriksson; Beáta Szeitz; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Runyu Hong; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Qimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Peter Horvath; Leticia Szadai; József Tímár; Sarolta Kárpáti; A Marcell Szász; Johan Malm; David Fenyö; Henrik Ekedahl; István Balázs Németh; György Marko-Varga
Journal:  Clin Transl Med       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.